CNBC Investing Club

Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites

A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.
George Frey | Reuters

Large-cap biopharma is a "key sector to own" right now, according to Credit Suisse — a view we share that is reflected in the composition of our new 10 core-holdings list.